P
Promentis Pharmaceuticals
Developing antipsychotic drugs to treat schizophrenia
About Promentis Pharmaceuticals
Promentis Pharmaceuticals, Inc. is a privately held biopharmaceutical company focused on the discovery and development of first-in-class therapies for the treatment of neuropsychiatric disorders. The company operates in the biopharmaceutical sector, specifically targeting central nervous system (CNS) disorders. Promentis develops novel oral compounds that engage System xc, a CNS target for diverse psychiatric conditions. The company's business model revolves around research and development (R&D) of these innovative therapies, aiming to bring them to market through clinical trials and regulatory approval. Revenue generation is primarily expected from the commercialization of these therapies, either through direct sales or partnerships with larger pharmaceutical companies. Promentis serves patients suffering from neuropsychiatric disorders, healthcare providers, and the broader medical community. The market it operates in is highly specialized and competitive, with a focus on addressing unmet medical needs in CNS disorders.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | Dec 2019 | $2.5M | $10M | Undisclosed | — |
| GROWTH EQUITY VCOther financing | Sep 2017 | $18M | — | Undisclosed | — |
Growth signals
Latest recorded traffic for Promentis Pharmaceuticals is 1.3K monthly website visits, up 78.1% over the last three months. Promentis Pharmaceuticals's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Promentis Pharmaceuticals in the Milwaukee ecosystem
The Promentis Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Golden Angels Investors
National Institutes of Health
Series A1 investor entered at this stage
- BIBlack Horse Investments
Series B and later4 investors entered at this stage
Other known investors3 additional known investors
Marquette University
University of Montana
University of Wisconsin-Milwaukee
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Promentis Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Promentis Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.












